Source/Disclosures
Source:

Press Release

Disclosures: Kato is an employee of Shionogi Inc. Wunderink is the principal investigator on the phase 3 APEKS-NP trial.
September 28, 2020
1 min read
Save

FDA approves cefiderocol for hospital-acquired, ventilator-associated bacterial pneumonia

Source/Disclosures
Source:

Press Release

Disclosures: Kato is an employee of Shionogi Inc. Wunderink is the principal investigator on the phase 3 APEKS-NP trial.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has approved Fetroja for patients aged 18 years or older with hospital-acquired and ventilator-associated bacterial pneumonia, Shionogi announced.

The approval is based on results from the phase 3 APEKS-NP trial, which showed that Fetroja (cefiderocol) was noninferior to high-dose extended-infusion meropenem in regard to all-cause mortality 14 days following initiation.

“Nosocomial pneumonia is one of the most common hospital-acquired infections and a rising number are caused by difficult-to-treat, multidrug-resistant pathogens, which can be a deadly threat for patients,” APEKS-NP principal investigator Richard G. Wunderink, MD, professor of pulmonary and critical care at the Northwestern University Feinberg School of Medicine, said in a press release. “The results from the APEKS-NP study show that cefiderocol is a much-needed additional option for the treatment of patients with [hospital-acquired bacterial pneumonia] and [ventilator-associated bacterial pneumonia] due to multidrug-resistant gram-negative bacteria.”

The FDA accepted a supplemental new drug application for the indications and granted cefiderocol priority review in early June.

Ventilator-associated and nosocomial bacterial pneumonia are often caused by gram-negative bacteria such as Acinetobacter baumannii complex, Escherichia coli, Enterobacter cloacae complex, Pseudomonas aeruginosa, Klebsiella pneumoniae and Serratia marcescens.

“Antimicrobial resistance is a major global health concern, and there is a clear need for new treatments such as Fetroja to give clinicians more options to fight life-threatening infections caused by gram-negative pathogens,” Shionogi President and CEO Akira Kato, PhD, said in the release.